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Abstract
The clinical relevance of serum c-glutamyltransferase (GGT) activity, in areas other than hepatic function, has recently been increased
by several epidemiological associations. Still, GGT remains a nonspeciﬁc test because of the inﬂuence of various pathophysiological fac-
tors. We devised a procedure based on gel ﬁltration chromatography, followed by postcolumn injection of ﬂuorescent GGT substrate (c-
glutamyl-7-amido-4-methylcoumarin), permitting the quantiﬁcation of GGT fractions in serum or plasma. Plasma GGT molecular
weight distribution was analyzed in healthy volunteers (20 males; mean ± SD age 38 ± 10 years; 20 females; age 44 ± 13; total GGT
21 ± 11 for males vs 13 ± 7 for females; P < 0.01). The method is highly sensitive (determination limit: 0.5 U GGT/L), with a linear
dynamic range between 0.5 and 150 U/L for each fraction. Four GGT fractions of diﬀerent molecular weight were detected in all subjects
of both genders: b-GGT, m-GGT, s-GGT (likely lipoprotein-bound, molecular masses >2000, 940, and 140 kDa, respectively), and a free
fraction (f-GGT, 70 kDa). f-GGT and s-GGT were the main fractions in subjects with lower and higher total GGT activity, respectively.
Higher total GGT activity in males is related mainly to f-GGT (P < 0.01). GGT fraction analysis may increase the sensitivity and spec-
iﬁcity of the GGT activity test.
 2007 Elsevier Inc. All rights reserved.
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Elevation of serum c-glutamyltransferase (GGT)1 activ-
ity is frequently interpreted as an index of hepatobiliary
dysfunction and as a nonspeciﬁc marker of excessive alco-
hol use [1]. However, more recent studies have demon-
strated that serum GGT, at values within the reference
range, is associated with evolution of the atherosclerotic
process [2,3], and predicts the onset and outcome of related
diseases. In particular, type II diabetes [4,5] and metabolic
syndrome (from the Framingham study) [6], coronary
artery disease-related events, and stroke are predicted by
serum GGT activity levels; this evidence has come from
studies conducted either in unselected populations [7–9]
or in patients known to have cardiovascular disease [10].
Furthermore, its prognostic value has been demonstrated
in kidney disease [11], hepatobiliary disease, and neo-
plasms, even those without hepatic involvement [12]. This
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conﬁrms earlier epidemiological studies indicating the pre-
dictive value of serum GGT in overall and cardiac mortal-
ity [13–15].
At present, however, the nonspeciﬁcity of the test [1]
makes risk stratiﬁcation based on total serum GGT activity
in patients with systemic, metabolic, and cardiovascular
diseases unsuitable.
GGT is present in serum as part of several molecular
complexes, with distinct physicochemical properties [16–
18]; some have been associated with speciﬁc diseases, for
example, intra- and extrahepatic jaundice [19], hepatocellu-
lar carcinoma [20], and cirrhosis and alcoholic liver disease
[21]. Unfortunately, the low sensitivity and reproducibility
of the diﬀerent procedures adopted so far to separate and
detect multiple forms of serum GGT have allowed the
assessment of GGT fractions only in subjects with GGT
values above the reference range, yielding conﬂicting
results as far as the number and biological signiﬁcance of
GGT fractions are concerned.
The aim of the present study was therefore to develop a
sensitive and reproducible procedure for the determination
of distinct serum GGT fractions in subjects with serum
GGT activity within the reference range of this enzyme.
This would allow its clinical use in prognostic stratiﬁcation
for cardiovascular events by eventual deﬁnition of speciﬁc
predictive GGT fraction proﬁles; moreover, it might permit
us to describe speciﬁc GGT fraction proﬁles for each clin-
ical condition with associated high GGT.
The new procedure is based on liquid chromatography
for the separation of GGT fractions on the basis of their
molecular weight and is coupled with a postcolumn enzy-
matic reaction in which a ﬂuorescent substrate (c-glutam-
yl-7-amido-4-methylcoumarin) is hydrolyzed to release
ﬂuorescent 7-amino-4-methylcoumarin [22–24]. We chose
this substrate because it is more sensitive than the poten-
tially carcinogenic 4-nitroanilide derivatives normally
adopted for routine determination of serum GGT [25,26].
This method was applied to the analysis of plasma samples
obtained from healthy volunteers.
Materials and methods
Chemicals and stock solutions
c-Glutamyl-7-amido-4-methylcoumarin (cGluAMC,
G7261), glycylglycine (GlyGly, G1002), bovine c-glutam-
yltransferase (G8040), c-glutamyl-4-nitroanilide (cGlu-
NA, G1135), and a kit for molecular weight markers
(MWGF1000; blue dextran, thyroglobulin, apoferritin,
b-amylase, bovine serum albumin, carbonic anhydrase)
were purchased from Sigma–Aldrich. Analytical
reagent-grade chemicals were used without further puri-
ﬁcation. cGluAMC solution was prepared by adding
3.6 mmol/L in 0.005 N NaOH and immediately diluted
20-fold into 0.25 M Tris–HCl buﬀer, pH 8.5 (25 C).
This stock solution was prepared weekly and stored at
+4 C.
Subjects
Fasting blood samples were obtained between 8:00 and
9:00 from 40 healthy individuals (20 males, mean ± SD
age 38 ± 10 years, range, 21–54; 20 females, age 44 ± 13
years, range 22–60), with serum GGT values between 6
and 47 U/L for men and between 6 and 34 U/L for women.
The presence of acute or chronic diseases was excluded
by clinical examination and laboratory tests.
Laboratory analyses
Total plasma GGT values were determined by enzyme
kinetic assay (Beckman Synchron CX 9-PRO analyzer).
Within-run and between-run variation (coeﬃcient of varia-
tion, %) was 3.5%; reference values by this procedure (5th
and 95th percentile) were 10–54 U/L for males and 7–28 U/
L for females (determination performed at 37 C). Blood
was collected into tubes containing EDTA as both antico-
agulant and antioxidant. After centrifugation (1500g,
10 min) at room temperature, plasma samples were stored
at 20 C and analyzed within 1 month. The study was
approved by the institutional ethics committee, and all sub-
jects gave informed consent.
Chromatographic apparatus and conditions
A HPLC System Gold apparatus (Beckman 126)
equipped with a 100-lL loop and a spectroﬂuorometric
detector (821-FP, Jasco) was used. Separation was per-
formed by gel ﬁltration chromatography using a Superose
6 HR 10/300 GL column (GE Healthcare) by isocratic elu-
tion with 0.1 mol/L sodium phosphate buﬀer (pH 7.4) con-
taining 0.2 mol/L NaCl, 0.1 mmol/L EDTA, and
5.4 mmol/L GlyGly to support GGT reaction [25]. Flow
was set at 0.5 mL/min. The column was calibrated for
molecular weight determination using a mixture of stan-
dard proteins of known molecular weight. Plasma samples
were ﬁltered with a 0.45-lm PVDF ﬁlter (Millipore) before
injection. Total run time was 50 min.
Online GGT fraction determination
The ﬂow eluting from HPLC column was mixed post-
column in a low-dead-volume mixing tee with the cGlu-
AMC ﬂuorescent substrate delivered by a syringe pump
(Braun) operating at a ﬂow rate of 0.1 mL/min. Enzymatic
reaction proceeded for 4.5 min [24] in a reaction coil (PFA,
2.6 mL) kept at the constant temperature of 37 C in a
water bath. The pH in the reaction coil after mixing was
8.2. AMC signal was speciﬁcally detected by a ﬂuorescence
detector operating at excitation wavelength kex = 380 nm
and emission wavelength kem = 440 nm [23]. Intensity of
ﬂuorescence signal was expressed in arbitrary ﬂuorescence
units (f.u.).
A pooled sample from 10 diﬀerent subjects was analyzed
through gel ﬁltration chromatography, and GGT activity
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fractions were collected, concentrated with a 3-kDa ultra-
ﬁltration membrane (Amicon, Millipore USA), and rechro-
matographed, as described above.
Oﬄine GGT fraction determination
Spectrophotometric determination of GGT was per-
formed using cGluNA as substrate and GlyGly as trans-
peptidation acceptor [26]. The amounts of p-nitroaniline
formed were measured by reading the absorbance at
405 nm. GGT activity of chromatographic fractions
(V = 0.5 mL) was measured in 96-well microtiter plates
after incubation (4 h, 37 C) of 100 ll of each fraction with
200 ll of reaction mixture. For spectrophotometric deter-
minations, a multilabel plate reader was used (Wal-
lac1420-Victor3, Perkin–Elmer).
Statistics
Correlations between various variables were presented
as the squared Pearson correlation coeﬃcient (r2 value),
and linear regression analyses were performed to assess
associations. GGT fraction values were compared with
the nonparametric Mann–Whitney test because of the
skewness of the GGT distribution. P < 0.05 was considered
signiﬁcant.
Results
Optimization of online GGT reaction
The HPLC apparatus coupled to the postcolumn reac-
tion system and spectroﬂuorometric detector was operated
in ﬂow injection mode, to optimize the online determina-
tion of GGT activity. Injections of commercial bovine
GGT solution were used to optimize the concentration of
the acceptor GlyGly (varying between 1 and 20 mmol/L)
and cGluAMC (varying between 0.1 and 50 lmol/L). Max-
imum signal/noise ratio was obtained at 4.5 mmol/L Gly-
Gly and 30 lmol/L cGluAMC. The calibration curve for
GGT under these optimized conditions was linear in the
range 0.5–150 U/L, with a sensitivity factor (±SD) of
3.81 ± 0.12 f.u. · min · L · U1 (r2 = 0.95, P < 0.001,
n = 7) and a determination limit of 0.5 U/L (detection
limit = 0.167 U/L).
Application: Plasma GGT elution proﬁles
The proposed method, under the operating conditions
described above, was applied to the analysis of plasma
samples obtained from healthy subjects. Fig. 1 shows the
online GGT-speciﬁc elution proﬁles of a representative
plasma sample obtained by using the liquid chromato-
graphic system coupled to a postcolumn reaction with
cGluAMC and ﬂuorescence detection. The proﬁle obtained
with the online procedure was completely superimposable
on that obtained by using cGluNA as substrate and
determining oﬄine GGT activity in the collected fractions.
Under these conditions, reagent cost was approximately 1
Euro for each analysis.
All GGT activity elutes between 10 and 25 mL. On the
basis of the molecular weight calibration curve of the col-
umn, four elution broad peaks can be identiﬁed for all sam-
ples and are deﬁned as big-GGT (b-GGT, eluting between
10.0 and 13.5 mL, MW > 2000 kDa), medium-GGT (m-
GGT, eluting between 13.5 and 16.6 mL, MW 940 kDa),
small-GGT (s-GGT, eluting between 16.6 and 20.4 mL,
MW 140 kDa), and free-GGT (f-GGT, eluting between
20.4 and 25 mL, MW 70 kDa).
Collection, concentration, and rechromatography of the
f, b, m, and s fractions led to single peaks at the original
elution volume.
Reproducibility
Reproducibility was determined by calculating both
within-day and between-day coeﬃcients of variation
(CVs), by using a pool, obtained by mixing 10 distinct
plasma samples. Within-day and between-day CVs for
total area were 3.1% (n = 3) and 2.2% (n = 5), respectively.
Quantiﬁcation of GGT fractions
Quantiﬁcation of each GGT fraction was performed on
the basis of a calibration curve obtained by plotting the
total area under the four chromatogram peaks in the
region 10 to 25 mL as function of known total GGT
activity injected (Fig. 2). The calibration curve was linear
between 5 and 47 U/L (sensitivity factor ± SD =
1.6 · 105 ± 0.6 · 105 f.u · L2 · U1; intercept ± SD =
3.4 · 105 ± 1.1 · 105 f.u. · L; r2 = 0.952, P < 0.0001,
Fig. 1. Online GGT-speciﬁc elution proﬁle of a representative plasma
sample of a healthy subject with total plasma GGT activity 31 U/L
(continuous line, left y axis). Oﬄine GGT proﬁle of the same plasma
sample obtained by using cGluNA as substrate and determining enzyme
activity in the collected chromatography fractions (dashed line, right y
axis). Vertical lines represent GGT fraction elution limits.
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n = 40). GGT activity associated with each GGT fraction
was calculated by dividing the area of each single peak
by the sensitivity factor; peak area was calculated using
the x axis as baseline and the elution limits reported above.
Table 1 and Fig. 3 summarize the results obtained with the
40 samples examined: higher values of total plasma GGT
activity in males (P < 0.01) were reﬂected by a signiﬁcant
diﬀerence in f-GGT activity (P < 0.01).
Although a positive linear correlation was observed
between total plasma GGT activity and activity of each
of four GGT fractions (Table 2), their relative contribu-
tions to total GGT activity were diﬀerent in both genders
(Fig. 4). In fact, in subjects with lower GGT activity, f-
GGT was the dominant fraction (up to 75%), whereas in
subjects with higher GGT values, f-GGT contribution
decreased to 20%, with a relative increase in s-GGT and
b-GGT fractions.
Discussion
Our method permits the sensitive and reproducible
determination of four serum GGT fractions in all plasma
samples examined (Fig. 1), with a considerably higher sen-
sitivity; the determination limit, in fact, was 0.5 U/L for
each fraction, as compared with 5 U/L—total plasma
activity value—for the routine method.
The molecular weights determined for the b-GGT, m-
GGT, and s-GGT fractions are compatible with lipopro-
tein-associated enzyme, that is, very low density lipopro-
tein, low-density lipoprotein and high-density lipoprotein,
as previously proposed [16,17], while indicating a free
enzyme form for f-GGT. Nevertheless, the gel ﬁltration
elution volumes of individual fractions (i.e., their molecular
weights) did not change, independently of the amount of
associated GGT activity (Fig. 1). This suggests a speciﬁc
interaction of GGT enzyme with each lipoprotein particle,
rather than aspeciﬁc absorption of lipophilic GGT to circu-
lating lipoproteins; the latter would produce a shift in elu-
tion volume peaks, as a consequence of the varying extents
of GGT protein absorption.
As expected [1], males had a higher total GGT value
than females: this diﬀerence was due mainly to higher
f-GGT levels (Table 1 and Fig. 3). In addition, we found
that, within the reference values for the routine method,
in healthy subjects of both genders (Fig. 4) f-GGT, the
‘‘free enzyme,’’ was the predominant fraction in the pres-
ence of low serum GGT levels, whereas higher total
Fig. 2. Linear correlation between total area under the chromatographic
curve (between 10 and 25 mL, elution volume) and total plasma GGT
values. y = 1.6 · 105x + 3.4 · 105; r2 = 0.952; P < 0.0001; n = 40.
Table 1
Total and fractional GGT activities (mean ± SD, U/L) in both genders
Males (n = 20) Females (n = 20) P
GGT total 21.3 ± 11.1 13.1 ± 1.6 <0.01
b-GGT 2.6 ± 2.3 1.6 ± 1.1 NS
m-GGT 1.0 ± 0.7 0.7 ± 0.4 NS
s-GGT 8.1 ± 6.0 5.1 ± 4.4 NS
f-GGT 11.5 ± 4.1 8.2 ± 2.5 <0.01
Note. The nonparametric Student t test was applied. NS, not signiﬁcant.
Fig. 3. Distribution of total plasma GGT activity and GGT activity associated with each plasma fraction in males (A) and females (B). The box extends
from the 25th to the 75th percentile with a line at a median. The highest and lowest values are shown above and below the box, respectively. *Signiﬁcantly
diﬀerent as compared with the corresponding values for females (P < 0.01).
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GGT values corresponded to increased b-GGT and s-GGT
fractions, that is, higher-molecular-weight complexes.
The ability of our method to deﬁne the heterogeneous
nature of total GGT activity of plasma and to describe a
diﬀerent fraction proﬁle dependent on gender and changing
total GGT levels make it suitable for the purpose of better
characterizing the clinical value of plasma GGT activity in
various disease conditions. Moreover, the increase in GGT
fractions likely associated with lipoproteins, observed in
subjects with plasma GGT values in the high-normal
range, may explain the reported prognostic value of plasma
GGT activity in cardiovascular diseases [6,7,10]. Conceiv-
ably, further studies might allow the association of varia-
tions in speciﬁc plasma GGT fractions with other disease
conditions.
The potential eﬀects of variation in very low density
lipoprotein, low-density lipoprotein, and high-density lipo-
protein and their ratios on GGT fractions may have impor-
tant clinical correlates. Total serum GGT activity is
known, from epidemiological studies, to be positively asso-
ciated with total cholesterol and triglycerides, and large
prospective studies are needed to clarify whether the prog-
nostic relevance of lipid/lipoprotein concentration is asso-
ciated with speciﬁc GGT fraction proﬁles. Furthermore,
pharmacological studies could clarify if drug modulation
of plasma lipids and its expected prognostic beneﬁts are
associated with possible peculiar modiﬁcation of GGT
fractions.
In conclusion, GGT fraction analysis is a reproducible
and sensitive method, suitable for studying qualitative
and quantitative distributions of GGT activity in plasma.
Further studies on selected patient cohorts will establish
precise connections between individual GGT fractions
and their determinants, and their clinical value in various
disorders.
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